NFKB1 and diffuse large B-cell lymphoma: Indeed, the highly selective IRAK4 inhibitors ND-2158 and ND-2110 abrogate aberrant NF-κB activation induced by oncogenic MyD88L265P and thus efficiently suppress the growth of ABC DLBCL cells in vitro and in vivo [50].